

Special Issue

Personalized Diagnosis, Treatment, and Prognosis of Parkinson's Disease

Message from the Guest Editors

Although effective treatments for the symptom control of Parkinson's disease (PD) have been developed in the past 20 years, it remains a clinical diagnosis based on motor and nonmotor signs and symptoms. Our understanding of the pathophysiology, phenotypic diversity, and progression of Parkinson's disease remains unsatisfactory. This Special Issue "Personalized Diagnosis, Treatment, and Prognosis of Parkinson's Disease" aims to highlight the current state of science and showcase some of the latest findings in the field of PD. We invite researchers in this field to submit original research and review articles, including studies on the discovery of novel biomarkers and new targets for therapeutic interventions to pave the path towards developing personalized medicine to achieve optimal health and wellness in PD.

Guest Editors

Dr. Cheng-Hsien Lu

Department of Neurology, Chang Gung Memorial Hospital-Kaohsiung and Chang Gung University, 123, Ta-Pei Road, Niao Sung district, Kaohsiung City 83304, Taiwan

Dr. Wei-Che Lin

Department of Diagnostic Radiology, Chang Gung Memorial Hospital-Kaohsiung and Chang Gung University, 123, Ta-Pei Road, Niao Sung District, Kaohsiung City 83304, Taiwan

Deadline for manuscript submissions

closed (31 October 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/101240

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).